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Background & Aims: Ileal malabsorption of bile salts is
observed in Crohn’s ileitis. We define the transcriptional
mechanisms involved in cytokine-mediated repression
of the rat apical sodium-dependent bile acid transporter
(ASBT). Methods: ASBT regulation was studied in IL-1–
treated IEC-6 and Caco-2 cells and in indomethacin-
treated rats. Results: Indomethacin-induced ileitis in
Lewis rats leads to specific reductions in ileal ASBT
messenger RNA and protein levels, whereas c-jun and
c-fos are induced. The proinflammatory cytokines inter-
leukin-1 and tumor necrosis factor repress the activity
of the ASBT promoter in Caco-2 and intestinal epithelial
cell-6 cells. This effect is blocked by the proteasome
inhibitor, MG-132, or by the phosphatidyl inositol 3-ki-
nase inhibitor, wortmannin. Indomethacin (in vivo) or
proinflammatory cytokine (in vitro) treatment leads to
serine phosphorylation and nuclear translocation of c-
fos. Mutation of a 5 activated protein (AP)-1 site inac-
tivates the ASBT promoter, whereas mutation of the 3
site abrogates the proinflammatory cytokine–mediated
repression. The 5 site binds a c-jun homodimer,
whereas the 3 site binds a c-jun/c-fos heterodimer.
c-Jun overexpression enhances ASBT promoter activity,
whereas a dominant negative c-jun construct inactivates
the promoter. c-Fos overexpression represses promoter
activity. A 27 base pair cis-element from the 3 site in
the ASBT promoter imparts cytokine-mediated down-
regulation to a heterologous SV40 promoter construct.
Conclusions: The ASBT promoter contains 2 distinct cis
AP-1 elements; the 5 element binds homodimeric c-jun
and mediates basal transcription. Inflammation is asso-
ciated with up-regulation, phosphorylation, and nuclear
translocation of c-fos, which then represses ASBT pro-
moter activity via binding of the 3 AP-1 element by a
c-fos/c-jun heterodimer.
Intestinal reclamation of bile salts is a key componentof the enterohepatic circulation of bile acids.1 A num-
ber of transporters are involved in this process, includ-
ing the apical sodium-dependent bile acid transporter
(ASBT), which is found on the apical surface of ileal
enterocytes, renal proximal convoluted tubule cells, large
cholangiocytes, and gallbladder epithelial cells.2–7 Com-
plete genetic disruption of ASBT activity leads to con-
genital primary bile acid malabsorption.8,9 Pathologic
bile acid malabsorption occurs in the setting of ileal
inflammation or resection, and exacerbates the morbidity
of Crohn’s disease by potentiating diarrhea, and with
extensive malabsorption, leads to depletion of the bile
acid pool with the subsequent development of cholesterol
gallstones and steatorrhea.10–15 A rabbit model of ileitis,
which was induced by enteral administration of Eimeria
magna, is associated with a significant down-regula-
tion of ASBT function, protein, and messenger RNA
(mRNA).16 Similarly, expression of ASBT mRNA is
repressed in a hamster 2,4,6-trinitrobenzenesulfonic acid
ileitis model.17 The molecular mechanisms underlying
the inflammation-mediated down-regulation of ASBT
are unknown, but are presumably related to increased
levels of proinflammatory cytokines such as interleukin
(IL)-1, IL-6, and tumor necrosis factor (TNF).18
The transcriptional regulation of ASBT is dependent
on both activated protein (AP)-1 and hepatocyte nuclear
factor-1.19,20 Site-directed mutagenesis of either AP-1
or hepatocyte nuclear factor-1 sites in the proximal
regions of rat and human ASBT promoters abrogates
transcriptional activity in transient transfection studies.
Similarly, overexpression of hepatocyte nuclear factor-1
and c-jun drives ASBT promoter construct activity. A
Abbreviations used in this paper: ABP, apical sodium-dependent bile
acid transporter binding protein; AP-1, activated protein-1; ASBT, api-
cal sodium-dependent bile acid transporter; bp, base pair; dAP-1,
downstream activator protein-1; IEC-6, intestinal epithelial cell-6; IL,
interleukin; pCMV, cytomegalovirus; SV40, simion virus 40; TNF, tumor
necrosis factor; uAP-1, upstream activator protein-1.




hepatocyte nuclear factor-1 knockout mouse is charac-
terized by absent ileal ASBT expression and by marked
fecal bile acid wasting.19 The expression of ASBT along
the longitudinal axis of the rat small intestine and during
normal rat ileal development correlates with the expres-
sion of c-jun.20 Activation of AP-1 is a well-known part
of the standard inflammatory cascade.21 Thus, it is not
immediately obvious how inflammation, which up-reg-
ulates a transcription factor implicated in stimulation of
ASBT expression, might instead lead to repression of this
bile acid transporter molecule.
The following studies showed 2 distinct AP-1 ele-
ments in the rat ASBT proximal promoter. One element,
which is bound by a c-jun homodimer, is involved in
basic promoter activity, whereas the other element binds
a c-fos/c-jun heterodimer, under inflammatory condi-
tions, and mediates ileitis-associated or IL-1–stimu-
lated down-regulation of ASBT expression.
Materials and Methods
Indomethacin-Induced Ileitis
All animal studies were approved by the Animal Care
and Use Committees at the Mount Sinai School of Medicine
and at the University of North Carolina. Acute ileitis was
induced in female Lewis rats (180–200 g) by subcutaneous
injection of 10 mg/kg of indomethacin daily for 2 days.22,23
Control animals were injected with sodium bicarbonate/10%
ethanol vehicle only. Forty-eight hours after the first indo-
methacin injection, the terminal ileum was removed. The
number of ulcers was quantified; ileal mucosa was removed by
scraping and was immediately snap frozen in liquid nitrogen.
RNA preparation and Northern blot analysis. To-
tal RNA was obtained from 100 mg of ileal mucosal scrapings
by using the TRIZOL extraction method (Gibco BRL, Rock-
ville, MD).24 Ten micrograms of total RNA was subjected to
1% formaldehyde gel electrophoresis and transferred to nylon
membranes (Osmonics Inc., Westborough, MA). Blots were
hybridized with radiolabeled complementary DNA probes
(ASBT,3 I100,25 c-jun,26 c-fos27), and signal intensity was quan-
tified as previously described.3 To examine RNA sample load-
ing differences, the same blots were reprobed with a 28S
ribosomal RNA oligonucleotide probe.28
Protein preparation and Western blot analysis.
Brush border membrane vesicles were prepared from ileal
mucosal scrapings by using cation precipitation as previously
described.29 Nuclear proteins were prepared as described be-
low. For Western blot analysis, 10 g of ileal brush border
membrane vesicles, 20 g of nuclear or cytoplasmic proteins,
or the entire c-fos immunoprecipitate (below) was used. Sam-
ples were electrophoresed on 12% sodium dodecyl sulfate–
polyacrylamide gels overlaid with 4% of acrylamide stacking
gel. The proteins were transferred to Hybond-C nitrocellulose
membrane (Amersham, Piscataway, NJ), followed by blocking
of nitrocellulose blots overnight at 4°C with 5% (wt/vol)
nonfat dry milk in Tris-buffered saline containing 0.1%
Tween 20 (Sigma, St. Louis, MO). ASBT protein was quanti-
fied with a phosphorimager by using a previously characterized
rabbit polyclonal antipeptide antibody and 125I-labelled pro-
tein A.3,29 Anti–c-jun and anti–c-fos antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) were added at a dilution of
1:1000, and blots were incubated for 1.5 hours at room
temperature. Anti–-actin (Sigma, St. Louis, MO) and anti-
histone H1 (Santa Cruz Biotechnology) were added to examine
the loading of cytoplasmic and nuclear proteins, respectively.
Antiphosphoserine antibody (CalBiochem, La Jolla, CA) was
added to detect serine phosphorylation in the immunoprecipi-
tated c-fos proteins. Immunoreactive bands were visualized by
chemiluminescence, and quantification was performed by densi-
tometry of autoradiographs in the linear range of detection.
Cell Culture
The human colon epithelial cell line Caco-2 (HTB-37;
American Type Culture Collection, Rockville, MD) was se-
lected and used in most experiments because it contains all the
trans-acting factors required for ASBT expression.20 In several
studies, intestinal epithelial cell (IEC)-6 cells (CRL-1592,
American Type Culture Collection), a rat small intestine epi-
thelial cell line, were used. All cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 4 mmol/L glu-
tamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 1.0
mmol/L sodium pyruvate, 0.1 mg/mL human transferrin, and
10% fetal calf serum. Cells were grown at 37°C and in 5% CO2.
Cytokines and cell stimulation. All the materials
were purchased from Sigma, unless otherwise indicated.
Caco-2 cells were treated for 40 hours with 20 pg/mL IL-1,
100 ng/mL TNF, 2 ng/mL IL-6, 20 mol/L MG-132
(BIOMOL Research Laboratories, Inc., Plymouth Meeting,
PA) or 25 nmol/L wortmannin. The dose dependency of the
effects of IL-1 or TNF on ASBT promoter-directed luciferase
expression was assessed in ASBT promoter transfected cells
that were treated for 40 hours at various concentrations (IL-1
[1, 5, 10, 15, 20 pg/mL] or TNF [10, 25, 50, 75, 100 ng/mL])
of the agents. The roles of NF-B and phosphatidylinositol
3-kinase in ASBT regulation were examined in Caco-2 cells
that were pretreated with 20 mol/L MG-132 or 25 nmol/L
wortmannin for 1 hour, followed by treatment of the cells with
IL-1 for various times (0, 6, 12, 18, 24, or 36 hours).
Plasmid Constructs
A series of hybrid plasmid constructs containing dif-
ferent ASBT 5 sequences and a downstream firefly luciferase
reporter gene were generated to localize the promoter cis
elements, as described previously.20 One of the constructs,
pGL3-ASBT5/208/118, which contains the shortest ASBT 5
promoter sequence, was used in the current studies. This
construct contains a downstream 326-base pair (bp) ASBT 5
sequence that possesses major promoter activity. This activity
is mediated by an AP-1 cis element that is located 23 bp
upstream of the transcription initiation site.
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The role of the downstream AP-1 (dAP-1) cis-trans interac-
tions in the regulation of ASBT5 promoter activity was
investigated by site-directed mutagenesis (see below) and by
introducing this element in a heterologous promoter system. A
45-bp DNA fragment (ASBT sequence in capital letters, con-
sensus sequence underlined, and restriction site linker in
lowercase letters) containing a 27-bp dAP-1 sequence (5-
ggcaagcttGGACTTTTTATGATTCATTATTTGTGCccatgg-
ccg-3) was synthesized. It was then subcloned (SV40/dAP-1)
downstream of the SV40 promoter found in the luciferase
reporter plasmid pGL3-Promoter (Promega, Madison, WI). A
corresponding control plasmid, SV40/ZErO, was made by
insertion into the same site of a nonspecific, 27-bp pZErO-1
plasmid DNA sequence (5-ggcaagcttGGTACCGAGCTCG-
GATCCACTAGTAACccatggccg-3).
The roles of c-jun and c-fos in ASBT5 promoter-mediated
gene expression were investigated by using positive and dom-
inant-negative expression vectors. Reporter assays were per-
formed by using cells cotransfected with pGL3-ASBT5/208/118
and a c-jun–containing (pCMV/c-Jun) or a c-fos–containing
plasmid (pCMV/c-Fos; generous gifts from Dr. Scott Plevy,
Mount Sinai School of Medicine, New York, NY). pCMV/
c-Jun and pCMV/c-Fos contain intact human c-jun and c-fos
genes that encode functional c-jun and c-fos proteins, respec-
tively.30 The c-jun–dominant negative plasmid pTAM-67
contains a c-jun sequence that has a 67-bp deletion of transacting
domain and an intact DNA-binding domain.31 The c-fos–
dominant negative plasmid pCMV500-8584hep-fosLZ(MO)
(Dr. Charles Vinson, National Cancer Institute, National In-
stitutes of Health, Bethesda, MD) harbors a 300-bp, transact-
ing domain-deleted c-fos gene sequence.32
Site-directed point mutagenesis. A QuikChange
Site-directed Mutagenesis Kit (Stratagene, LaJolla, CA) was
used to introduce specific mutations in pGL3-ASBT5/208/118,
following procedures as described by the manufacturer. Two
AP-1 elements were targeted, which are contained in the
ASBT 5 major promoter region P3, ranging from 208 to
118. The construct, pGL3-ASBT5/208/118, which has this
intact fragment inserted, was used as the template plasmid.
DNA oligos were synthesized and used as primers that contain
single-point mutations corresponding to 1 or 2 nucleotides of
the 2 AP-1 cis elements. As a result of the technique, 3
PCR-synthesized plasmids were made, pGL3-ASBT5/P3M1,
pGL3-ASBT5/P3M2, and pGL3-ASBT5/P3M3, which con-
tain point mutations in the upstream (uAP-1), downstream
(dAP-1), or both AP-1 sequences, respectively. The plasmids
were examined for their sizes by electrophoresis, and the point
mutations were confirmed by DNA sequencing.
Reporter assays. The procedures for transient trans-
fection and firefly luciferase analysis of cells were carried out as
described previously.20 All transfections were performed in
triplicate and replicated in 3 separate sets of experiments (i.e.,
9 individual data points for each experimental transient trans-
fection). Briefly, 5  106 cells per plate (3 plates per group)
were used in each transfection executed by electroporation at
0.22 kV and 950 F (Bio-Rad, Hercules, CA). Cells of each
plate were cotransfected with 4 g of the testing plasmid
constructs together with 0.1 g of a quantitative control
plasmid pRL-TK (Promega, Madison, WI) containing a thy-
midine kinase promoter–driven Renilla luciferase gene. For
cell transfections with dominant negative c-jun or c-fos, 20 g
of the plasmids were used. This insured that there was full
competition for the DNA-binding activities of the endogenous
counterparts. After electroporation, the cells were cultured for
an additional 40 hours before dual luciferase assays (Promega,
Madison, WI), using the standard procedures as described by
the manufacturer.
Cytoplasmic and nuclear protein extraction. Nu-
clear and cytoplasmic extracts were prepared from rat ileal
mucosal scrapings or cultured cells by using previously de-
scribed techniques.20 The procedures essentially described by
Zerivitz and Akusjarvi33 were used for preparations of cyto-
plasmic and nuclear extracts from logarithmically growing
Caco-2 cells untreated or treated for 40 hours with IL-1,
TNF, or IL-6. The methods were also used to prepare cyto-
plasmic and nuclear extracts from ileal epithelium of rat
injected with indomethacin or a vehicle control. The nuclear
and cellular extracts were dialyzed overnight, aliquoted into
vials, quick-frozen, and stored at 80°C. The concentrations
of nuclear and cellular proteins were determined by using a
Bio-Rad protein assay kit (Bio-Rad, Hercules, CA).
Band shift assays. Band shift assays were performed
with 5 g of cytoplasmic or nuclear proteins. Proteins were
incubated at 37°C for 30 minutes with 2  105 cpm of
32P-labelled DNA probe in 15 mmol/L KCl, 5 mmol/L MgCl2 ,
0.25 mmol/L EDTA, 0.25 mmol/L dithiothreitol, 12 mmol/L
Hepes (pH 7.9), 10% glycerol, and 200 ng/L Escherichia coli
transfer RNA.34 Band supershift assays were performed with
0.2 mg/mL of mouse antihuman c-jun or c-fos monoclonal
antibody (Santa Cruz Biotechnology). Unbound DNA se-
quences were digested for 30 minutes with 127 units of DNase
I (Gibco/BRL). Nonspecific protein binding was reduced by
adding 5 mg/mL heparin to the mixture for a 10-minute
incubation at room temperature. Samples were then subjected
to electrophoresis in a 7% native polyacrylamide gel with 0.5X
Tris-borate-EDTA running buffer. The gels were dried and
exposed to Kodak BIOMAX MS films (Kodak, Rochester, NY)
at 80°C.
Immunoprecipitation
The method described by Anderson and Blobel35 was
modified and used in immunoprecipitation experiments. Cy-
toplasmic and nuclear extracts prepared from ileal mucosal
scrapings or cultured cells were microcentrifuged for 30 min-
utes at 10,000g. The supernatants were precleared with 50 L
activated, quenched Sepharose by gently shaking for 1 hour at
4°C, followed by centrifugation for 5 minutes at 200g. The
supernatants (1 mL) were mixed with 25 L of a 1:1 slurry of
Ab (anti–c-fos 2 g/L)-Sepharose/Tris saline albumin solu-
tion (0.01 mol/L Tris, pH 8.0, 0.14 mol/L NaCl, 0.025%
NaN3), and were gently shaken for 1 hour at 4°C. The mix-
tures were then washed sequentially with 0.1% Triton X-100
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in Tris saline albumin solution, TSA solution and 0.05 M Tris,
pH 6.8. SDS/sample buffer (50 L) without 2-mercaptoetha-
nol was added to the Sepharose pellets and heated for 5
minutes at 100°C. After microcentrifugation for 5 seconds, the
supernatants were analyzed by Western blotting (see above).
Fluorescence confocal microscopy. Indirect im-
munofluorescence microscopy was performed on glass cover-
slip-grown Caco-2 cells according to previously published
methods.36 The cells were fixed and permeabilized for 7 min-
utes in 100% methanol at 20°C, followed by rehydration in
phosphate-buffered saline. Nonspecific sites were blocked with
normal goat serum (Gibco/BRL) for 60 minutes at room
temperature before incubation with the primary antibody,
mouse monoclonal anti–c-fos immunoglobulin G 2a (0.2 mg/
mL; Santa Cruz Biotechnology) diluted 1:100 with 2% bovine
serum albumin and 10% goat serum in phosphate-buffered
saline. Incubation was carried out for 60 minutes at room
temperature. After 5 washes with phosphate-buffered saline,
the cells were incubated with fluorescein goat antimouse im-
munoglobulin G (H  L) (2 mg/mL; Molecular Probes, Eu-
gene, OR) diluted 1:1000 with 0.5% bovine serum albumin in
phosphate-buffered saline for 30 minutes at room temperature
in the dark. After washing with phosphate-buffered saline,
cells on coverslips were inverted onto a drop of Vectashield
(Vector Laboratories Inc., Burlingame, CA). Fluorescence was
examined with a Leica TCS-SP (UV) 4-channel confocal laser
scanning microscope in the Imaging Core Facility Microscopy
Center, Mount Sinai School of Medicine. Image resolution
used a Leica 63 and/or 100 Neofluor objective, and the
Leica TCS-SP software was 512  512 pixels (Leica, North-
vale, NJ).
Statistical analysis. Analyses of data differences
were carried out by Student t test for analysis of 2 means and
by analysis of variance followed by Fisher’s PLSD post-hoc test
for multiple determinations. A value of P 	 .05 was consid-
ered statistically significant.
Results
Ileal Inflammation Significantly Upregulates
c-fos and c-jun and Reduces Steady-State
ASBT Expression
Ileitis was induced in Lewis rats by subcutaneous
injection of indomethacin. Indomethacin-injected rats
(n 
 6) had an average of 36 ulcers in the ileum (range,
19–55), whereas control injected rats (n 
 6) had none.
Phosphorimager quantification of Northern blot analysis
showed a marked reduction in steady-state ASBT mRNA
levels and equal RNA loading as assessed by quantifica-
tion of 28S ribosomal RNA (ASBT: indomethacin,
38,900  15,800 vs. control, 97,800  40,300,
P 	 0.001; 28S RNA: indomethacin, 9400  1300 vs.
control, 9100  1400, n 
 6 in each, P  0.05; Figure
1A ). Similarly, ASBT protein levels were reduced in
brush border membrane vesicles prepared from indo-
methacin-treated rats (indomethacin, 11,100  1800 vs.
control, 17,600  3100, n 
 4 in each, P 	 0.05,
Figure 1B). Steady-state mRNA levels for c-fos and
c-jun were up-regulated in indomethacin-induced ileitis
(c-fos: indomethacin, 422,800  282,100 vs. control,
136,300  55,600, P 	 0.0001; c-jun: indomethacin,
69,200  23,700 vs. control, 33,800  16,400, P 	
0.005; Figure 1A ). Total cellular c-fos and c-jun protein
expression were each increased by 50% (c-fos: indometh-
acin 137,500  15,600 vs. control 84,700  18,800,
P 	 0.05; c-jun: indomethacin 127,200  13,300 vs.
control 82,600  12,000, P 	 0.05; see Figure 1B).
Steady-state mRNA levels for I100, an ileal brush border
hydrolase,25 were unaffected in this model of ileitis (in-
domethacin 16,500  2000 vs. control 16,000  1800,
P  0.05; see Figure 1A ).
IL-1 and TNF down-regulate ASBT gene pro-
moter activity. Treatment of pGL3-ASBT5/208/118–
transfected Caco-2 cells with 20 pg/mL of IL-1 or 100
ng/mL of TNF resulted in significant reductions in
ASBT promoter-directed firefly luciferase expression
(Figure 2A ). Cells treated with IL-6 at the concentrations
of up to 2 ng/mL showed no significant reduction in
ASBT promoter activity, in comparison with the un-
treated cells. The inhibitory effect of IL-1 and TNF on
ASBT promoter-directed firefly luciferase expression was
also observed in the rat intestinal epithelial cell line
IEC-6 transfected with the plasmid construct pGL3-
ASBT5/208/118. Caco-2 cells transfected with pGL3-
ASBT5/208/118 were untreated or treated with various
concentrations of IL-1 (1, 5, 10, 15, 20 pg/mL) or TNF
(10, 25, 50, 75, 100 ng/mL), respectively. Dose-depen-
dent reductions in ASBT promoter-directed luciferase
expression were observed with IL-1 (Figure 2B) and
TNF (data not shown).
IL-1 mediated down-regulation of ASBT is inhib-
ited by MG-132 and wortmannin. The signal trans-
duction pathway between IL-1 and ASBT promoter
down-regulation was assessed by using MG-132 and
wortmannin. MG-132 is a potent cell permeable selec-
tive proteasome inhibitor that disrupts activation of
NF-B by inhibiting IB degradation.37 Wortmannin is
a selective inhibitor of phosphatidylinositol 3-kinase.38
Both MG-132 and wortmannin almost completely abro-
gated the effect of IL-1 on the ASBT promoter (Figure
3A ). The effect of MG-132 and wortmannin was ob-
served within 6 hours of exposure (Figure 3B). MG-132
abrogated the effect of IL-1 on both luciferase activity
and luciferase steady-state mRNA levels (Figure 3C ),
indicating that the effect was not simply a general effect
on protein degradation.
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Inhibitory effects of inflammatory cytokines on
ASBT expression are mediated in part by ABP-2–DNA
interactions. Previous studies have shown that at least
4 DNA-nuclear protein complexes, termed ABP-1, ABP-2,
ABP-3, and ABP-4, are detected at the ASBT 5 down-
stream region P3, which is involved in the transcriptional
regulation of expression of the bile acid transporter.20 One
Figure 1. (A) Effect of ileal inflammation on steady-state levels of ileal
ASBT, c-Jun, c-Fos, and I100 mRNA levels. Ten micrograms of each
total ileal RNA sample (indomethacin-induced ileitis [lanes 2, 4, and
6; each lane represents a separate animal] and control [lanes 1, 3,
and 5]) was analyzed by Northern blotting. Indomethacin-induced
ileitis is associated with repression of ASBT expression and enhance-
ment of both c-jun and c-fos. Both I100 and 28S ribosomal RNA are
unchanged. (B) Effect of ileal inflammation on ileal ASBT, c-jun, and
c-fos protein levels. ASBT protein in ileal brush border membrane
vesicles (10 g) and c-fos and c-jun protein in ileal cytoplasmic
extracts (5 g) were measured by Western blot analysis. Expression
of ASBT was repressed in the setting of indomethacin-induced ileitis
(lanes 2, 4, and 6), whereas c-jun and c-fos expression was increased.
Figure 2. (A) Down-regulation of ASBT promoter activity by IL-1 and
TNF. Caco-2 and IEC-6 cells transfected with the plasmid pGL3-
ASBT5/208/118 were untreated (Control) or treated for 40 hours
with IL-1, TNF, or IL-6 at the concentrations of 20 pg/mL, 100
ng/mL, and 2 ng/mL, respectively. The ASBT promoter activities
represented by firefly luciferase assay readings were measured as
described in Materials and Methods. In comparison with the control,
both cells treated with IL-1 and TNF, but not IL-6, expressed signif-
icantly reduced luciferase activities (P 	 0.001). All activities were
normalized to thymidine kinase promoter–driven Renilla luciferase
and each result is a mean of data obtained from at least 3 experi-
ments (same as in other experiments as shown in Figures 3, 5, 6, and
9). (B) IL-1 down-regulates ASBT promoter activity in a dose-depen-
dent manner. pGL3-ASBT5/208/118–transfected Caco-2 cells were
treated with IL-1 for 40 hours at different concentrations as shown.
The results show that ASBT promoter–directed firefly luciferase ex-
pression was reduced in dose-dependent fashion.
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of these complexes, ABP-2, includes the AP-1, c-jun. Its
presence correlates with developmental-stage and region-
specific expression of ASBT. In these studies, ABP-2 for-
mation was inhibited in Caco-2 cells treated with IL-1 or
TNF but not with IL-6 (Figure 4). An additional previously
undetected band that migrated faster than ABP-3 was also
reduced after IL-1 and TNF treatment.
Transcriptional activation and repression of ASBT
promoter activity are mediated by distinct AP-1 interac-
tions. The proximal promoter for ASBT contains 2 dis-
tinct AP-1 binding sites. Previous reporter assays showed
that site-directed point mutation of ASBT 5 uAP-1
(construct M1) or both uAP-1 and dAP-1 (construct M3)
led to significant and complete inhibition of ASBT pro-
moter activity. In light of the reduced baseline activity,
Figure 4. Effects of inflammatory cytokines on ASBT binding protein
(ABP)–DNA interactions. Band-shift assay was carried out to analyze
the interactions of ASBT promoter binding proteins with two AP-1
elements in ASBT promoter. The ASBT promoter fragment P3, which is
contained in the hybrid plasmid construct pGL3-ASBT5/208/118,
was radiolabeled and incubated with the nuclear extract from (lane 1)
untreated, (lane 2) TNF-, (lane 3) IL-1–, or (lane 4) IL-6–treated
Caco-2 cells. Four previously described ABPs are observed in the (lane
1) control cells. ABP2-DNA interaction was inhibited by treatment with
(lane 1) TNF and (lane 3) IL-1, but not with (lane 4) IL-6.
Š
Figure 3. (A) MG-132 and wortmannin abolish IL-1 inhibitory effects
on ASBT promoter function. pGL3-ASBT5/208/118–transfected
Caco-2 cells were untreated (Control) or treated for 40 hours with 20
mol/L MG-132 (I  M) or 25 nmol/L wortmannin (I  W) plus 20
pg/mL IL-1, followed by measurement of luciferase activities. Cells
treated with IL-1 alone (IL-1) served as a corresponding control for
the groups I  W and I  M. Both MG-132 and wortmannin completely
abrogate the inhibitory effect of IL-1 on ASBT promoter. (B) Time-
course studies of MG-132 and wortmannin inhibition of IL-1 effect.
The hybrid reporter construct-transfected cells were treated with ei-
ther MG-132 or wortmannin plus IL-1 as described previously, except
the incubation times varied as shown in the Figure. IL-1 treatment
leads to progressive reduction in ASBT promoter activity over 40
hours. The effect of IL-1 is immediately offset by simultaneous
treatment with either MG-132 or wortmannin. (C) Northern blot anal-
ysis of the effect of MG-132 on IL-1–mediated repression of ASBT
promoter activity. No luciferase mRNA (Luc) is detected in untrans-
fected Caco-2 cells (lane 1). Luciferase mRNA is observed in cells
transfected with pGL3-ASBT5/208/118 (lane 2) and steady-state
levels are markedly reduced if cells are pretreated with 20 pg/mL of
IL-1 (lane 3). MG-132 significantly reduces the effect of IL-1 on
luciferase mRNA levels (lane 4). Equal loading in all lanes is shown by
the signal for 28S RNA.
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no effect of IL-1 could be observed in M1 and M3. A
point mutation in dAP-1 (construct M2) did not affect
the promoter activity of P3.20 Surprisingly, the inflam-
matory cytokines IL-1 (Figure 5) and TNF (data not
shown) had no effect on M2-directed luciferase expres-
sion, in comparison with the untreated, M2-transfected
cells.
Insertion of dAP-1 sequence downstream of a
SV40 promoter mediates IL-1 down-regulation of re-
porter gene expression. The SV40-driven luciferase con-
struct, the pGL3 promoter, is not responsive to IL-1
(Figure 6). Insertion of a 45-bp DNA fragment that
contains dAP-1 downstream of this SV40 promoter
(SV40/dAP-1) modestly reduces baseline activity of the
promoter and imparts responsivity to 20 pg/mL of IL-
1. IL-1–mediated down-regulation is inhibited by
pretreatment with wortmannin. Insertion of a nonspe-
cific 45-bp fragment (SV40/ZErO) had no effect on basal
SV40 promoter activity and could not confer responsivity
to IL-1.
uAP-1 and dAP-1 sequences within the ASBT pro-
moter region differentially bind to the trans-acting fac-
tors under IL-1–stimulating condition. The 2 func-
tional sequences, uAP-1 and dAP-1, are located 23-bp
upstream and 18-bp downstream, respectively, of the
transcription initiation site (Figure 7A ); the location of
the latter for regulation of gene transcription is unusu-
al.20 The consensus sequence for the AP-1 binding site is
dependent on a terminal CA dinucleotide. The uAP-1
sequence contains a single cis element in the antisense
transcriptional template strand (Figure 7B), whereas the
dAP-1 sequence consists of 2 completely overlapping
AP-1 cis elements, d(n)-AP1 and d(s)-AP1, which exist
in the antisense and sense strands, respectively (Figure
7C ). Interestingly, the uAP-1 and d(n)-AP1 cis elements
in the antisense strand have the same type of sequence
(5-TT(G)AATCA-3), whereas the d(s)-AP1 cis element
in the sense strand is another type of AP-1 sequence
(5-TGATTCA-3).39
Further studies were performed in Caco-2 cells to
examine the trans-acting factors binding to the 2 AP-1
sequences under the IL-1–stimulating condition. Un-
der native and inflammatory conditions, uAP-1 bound to
nuclear (Figure 7D, lanes 3 and 9) and cytoplasmic
(Figure 7E, lanes 3 and 9) c-jun only, but not to c-fos
(Figure 7D–E, lanes 1 and 7). Under native conditions,
Figure 5. Site-directed mutagenesis of dAP-1 abolishes ASBT pro-
moter response to IL-1 inhibitory action. Plasmid constructs contain-
ing point mutations at uAP-1 (M1), dAP-1 (M2), or both (M3) were
prepared as described in Materials and Methods. Cells transfected
with pGL3-Basic (Basic) or pGL3-ASBT5/208/118 (P3), containing no
promoter or ASBT P3 promoter sequence were used as negative and
positive controls, respectively. Caco-2 cells transfected with these
plasmid constructs were untreated or treated with IL-1 for 40 hours,
followed by firefly luciferase assay. As shown, mutations of uAP-1
(M1) or both AP-1 sites (M3) resulted in a significant inhibition of
basal ASBT promoter activity (P 	 0.0001). The mutation of dAP-1
(M2) did not significantly affect ASBT promoter activity, compared with
the positive control (P3). However, dAP-1 mutation led to failure of
IL-1–mediated inhibition of ASBT promoter activity. Results are com-
piled from three separate experiments, each performed in triplicate.
Figure 6. The dAP-1 cis element confers IL-1 responsivity to an
SV40 promoter construct. The role of dAP-1 in ASBT promoter re-
sponse to IL-1 was assessed by inserting dAP-1 into a heterologous
promoter system. A hybrid plasmid construct SV40/dAP-1 was pre-
pared by insertion of a 45 bp, dAP-1-containing fragment into a site,
downstream of the SV40 promoter, of the plasmid pGL3-Promoter
(SV40), which has no intrinsic response to IL-1. Caco-2 cells trans-
fected with pGL3-ASBT5/208/118 (P3), or SV40/dAP-1 had marked
inhibitory responses to IL-1, which could be blocked by pretreatment
with wortmannin. A control hybrid construct SV40/ZErO containing a
45 bp, pZErO plasmid sequence inserted into the same site showed
no response to treatment with IL-1. Results are compiled from 3
separate experiments, each performed in triplicate.
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dAP-1 was bound by c-jun alone by using nuclear ex-
tracts (Figure 7D, lanes 2 and 4) and by c-jun and c-fos
by using cytoplasmic extracts (Figure 7E, lanes 2 and 4).
Under inflammatory conditions, dAP-1 bound both c-
jun and c-fos by using either nuclear or cytoplasmic
extracts (Figure 7D–E, lanes 8 and 10). A similar elec-
trophoretic mobility shift assay pattern was observed by
using ileal nuclear extracts from indomethacin-treated
rats (Figure 7F ). In vehicle-injected animals, dAP-1
bound c-jun (Figure 7F, lane 3) but not c-fos (Figure 7F,
lane 2). In indomethacin-treated animals, dAP-1 bound
both c-jun (Figure 7F, lane 6) and c-fos (Figure 7F,
lane 5).
Western analysis of cytoplasmic and nuclear extracts
of rat ileum showed that c-jun was present in both,
whereas c-fos translocated from the cytoplasm to the
nucleus after indomethacin treatment (Figure 8A ). In-
domethacin treatment was associated with serine phos-
phorylation of immunoprecipitated c-fos (Figure 8B).
Immunofluorescence confocal microscopy was performed
on Caco-2 cells treated with IL-1. Under native condi-
tions, c-fos was localized diffusely through cell in a
punctate pattern, whereas IL-1 treatment led to nuclear
translocation of c-fos (Figure 8C ).
c-Jun is a transcriptional activator and c-Fos is a
transcriptional repressor of the ASBT promoter. To fur-
ther study the roles of c-jun and c-fos in ASBT expres-
Š
Figure 7. IL-1 treatment of Caco-2 cells and indomethacin treatment
of rats leads to formation of fos/jun heterodimer and subsequent
binding to dAP-1. (A) Shows the schematic diagram of ASBT 5 major
promoter region P3, which was contained in the hybrid reporter con-
struct pGL3-ASBT5/208/118, upstream of the firefly luciferase re-
porter gene. Numbers in the diagram represent the sequence posi-
tions. The transcription initiation site is numbered by 0 and indi-
cated by arrow. The sequences of (B) uAP-1 and (C) dAP-1 oligo
probes used in the supershift assays (D and E) are shown. The AP-1
consensus sequences are indicated by underlined [uAP-1 and
d(n)AP-1] and above-lined (d(s)AP-1) nucleotides. The critical CA ter-
minal dinucleotide of the AP-1 binding site is italicized. The results
obtained from the electrophoretic mobility supershift assays with the
(D) Caco-2 nuclear extract and (E) cytoplasmic extract are shown.
Under both native (D and E, IL-1 ) and inflammatory (D–E, IL-1 )
conditions, uAP-1 element (u) binds to only c-jun (j) (D–E, lanes 3 and
9), but not c-fos (f) (D–E, lanes 1 and 7), as shown by the supershifted
ABP-2 (S-nABP-2 and S-cABP-2) and the nonsupershifted ABP-2
(nABP2 and cABP2), respectively. Conversely, under the native con-
dition, dAP-1 sequence (d) binds to only c-jun in nucleus (D, lanes 2
and 4), whereas the sequence binds both c-jun and c-fos from cyto-
plasm (E, lanes 2 and 4). Under the inflammatory condition, dAP-1
sequence binds c-jun and c-fos from nucleus (D, lanes 8 and 10) and
cytoplasm (E, lanes 8 and 10). The presence and absence of c-fos in
nuclear and cytoplasmic protein/dAP-1 complexes are represented by
the supershifted (S-nABP3 and S-cABP3) and nonsupershifted (nABP3
and cABP3) bands, respectively. D and E, lanes 5 and 6 represent no
antibody controls for the supershift analysis of uAP-1 and dAP-1
sequences, respectively. Indomethacin treatment of rats leads to an
(F ) electrophoretic mobility shift assay pattern similar to that observed in
IL-1–treated Caco-2 cells (D–E). The dAP-1 sequence binds c-jun but not
c-fos from ileal nuclear extracts of vehicle- (Indo-) treated rats (F, lanes 2
and 3), whereas after indomethacin treatment (Indo ), dAP-1 sequence
binds c-jun and c-fos from ileal nuclear extracts (F, lanes 5 and 6). u,
upstream; d, downstream; s, sense strand; n, antisense strand.
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sion, positive and dominant negative expression con-
structs were cotransfected in Caco-2 cells with the
reporter construct pGL3-ASBT5/208/118. As previ-
ously shown, c-jun trans-activates the ASBT promoter
(Figure 9A ). Interestingly, c-jun inhibits the activity of
pGL3-SV40/dAP-1 (Figure 9B). A dominant negative
c-jun construct abrogates ASBT promoter activity in both
Caco-2 (Figure 9A ) and IEC-6 cells (data not shown). In
contrast, overexpression of c-fos represses ASBT pro-
moter activity in Caco-2 cells (Figure 9A ). The domi-
nant-negative c-fos construct also represses ASBT pro-
moter activity (Figure 9A ). This c-fos mediated
repression of activity is also observed in the SV40-pro-
moter construct that harbors the dAP-1 element, but not
in SV40/Zero and SV40 promoter alone (Figure 9B).
Discussion
Intestinal inflammation is associated with a vari-
ety of abnormalities in solute transport.16,40–42 Clinical
Figure 9. c-Jun transactivates and c-fos represses ASBT promoter
activity via 2 distinct AP-1 binding sites. (A) Effects of overexpression
of wild-type and dominant negative jun and fos on ASBT promoter
activity. Caco-2 cells were transfected with pGL3-ASBT5/208/118
alone (Control) or cotransfected with plasmids containing wild-type
(jun, fos) or dominant negative [jun(-), fos(-)] c-jun or c-fos, respec-
tively, as described in Materials and Methods. Wild-type jun greatly
enhances ASBT promoter activity (P 	 0.01), whereas wild-type fos
and dominant negative jun and fos significantly suppress the pro-
moter function in comparison with the control (P 	 0.001). (B) dAP-1
from the ASBT 5 region mediates jun and fos inhibitory effect on
SV40 promoter activity. Luciferase assays with cells cotransfected
with the hybrid construct SV40/dAP-1 and the plasmids containing
wild-type c-jun or c-fos show that both the exogenous factors can
significantly inhibit SV40 promoter activity, which is not affected by
the 2 exogenous proteins in the presence of the promoter alone
(SV40) or a 27-bp pZErO-1 plasmid sequence downstream of SV40
(SV40/ZErO). Results are compiled from 3 separate experiments,
each performed in triplicate.
Figure 8. Inflammation is associated with phosphorylation and nu-
clear translocation of c-fos. (A) Indomethacin treatment induces
translocation of c-fos from cytoplasm to nucleus. The induction of rat
ileitis and preparation of cytoplasmic (c) and nuclear (n) extracts from
rat ileal mucosal scrapings are described in Materials and Methods.
Western blot analyses with 10 g of each sample were performed to
examine the localization of c-jun and c-fos under inflammatory condi-
tion. c-jun is present in both cytoplasm and nucleus under control
(saline) and ileitis (Indo) conditions, whereas c-fos exists in cytoplasm
under native condition and translocates to nucleus after ileitis was
induced. The same membrane was probed with actin and histone
antibodies for examination of the cytoplasmic and nuclear protein
loading, respectively. (B) c-fos protein is phosphorylated after ileitis is
induced. c-fos protein was precipitated from the nuclear and cytoplas-
mic extracts used in the above experiment and analyzed by Western
blot analysis using a specific phosphoserine antibody as described in
Materials and Methods. Phosphorylated c-fos (P-fos) is observed in
both the cytoplasm and nucleus after indomethacin treatment, but
not in the control condition. (C) c-Fos translocates to the nucleus in
Caco-2 cells treated with IL-1. The top panel shows immunofluores-
cent localization of c-fos in native Caco-2 cells. Immunofluorescence
is distributed throughout the cell in a punctate pattern. After IL-1
treatment, c-fos is found primarily within the nucleus (C bottom panel,
2 nuclei in field with the right one labeled with white arrow and N).
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studies in humans indicate that bile acid malabsorption
is observed in various forms of ileitis.11–15 Molecular
investigations have not yet been performed in humans to
determine if this is mediated by alterations in the ex-
pression or function of ASBT. Previously, 2 distinct
animal models had shown that ileitis induces marked
reductions in the expression of ASBT.16,17 The current
studies have shown that indomethacin-induced acute
ileitis in rats is also associated with a significant down-
regulation of steady-state ASBT mRNA and protein
levels. This finding does not appear to be a generalized
phenomenon that results from mucosal injury because
the expression of another brush border protein, I100, is
unaffected. As expected, the AP-1 transcripts, c-jun and
c-fos, were up-regulated in this model of ileitis. Indo-
methacin-induced ileitis has been previously shown in
our laboratories to be associated with increased expres-
sion of inflammatory cytokines, such as IL-1.23 There-
fore, further mechanistic investigations were performed
in Caco-2 and IEC-6 cells treated with inflammatory
cytokines.
Proinflammatory cytokines reduced the activity of the
rat ASBT promoter in both Caco-2 and IEC-6 cells.
Dose-dependent reductions in promoter activity were
observed using either IL-1 or TNF. The signal trans-
duction pathways involved in mediating the effects of
proinflammatory cytokines are quite complex.43 In this
in vitro system, transcriptional repression could be in-
hibited by pretreatment with either wortmannin or MG-
132, which block phosphatidylinositol 3-kinase and
proteasome activity, respectively. Phosphatidylinositol
3-kinase activity may be involved in the activation of
both AP-1 and NF-B.38,44 Proteasome function is im-
portant in mediating degradation of I-B and subse-
quent activation of NF-B. Therefore, IL-1 repression
of ASBT is mediated through both AP-1 and NF-B.
Activation of NF-B in this system may be via more
than 1 mechanism, including an I-B–independent sys-
tem. Northern and Western blot analysis indicated that
both c-jun and c-fos were up-regulated in response to ileal
inflammation. Previous investigations had indicated that
AP-1 played a key role in the transcriptional activation of
the rat ASBT promoter,20 thus the mechanism by which
activation of AP-1 might repress ASBT expression was
perplexing.
The ASBT promoter contains 2 distinct AP-1 cis-
elements, which permit the differential effects of AP-1
trans-acting factors (Figure 10). The uAP-1 site is a
positive-acting element, whereas the downstream site is
involved in transcriptional repression. The upstream el-
ement binds a c-jun homodimer. Our previous report, in
retrospect, incorrectly indicated that c-fos bound to
uAP-1.20 Those studies were performed with a large
fragment of ASBT 5 flanking DNA that included both
uAP-1 and dAP-1. The current investigations more thor-
oughly and specifically investigated the trans-acting fac-
tors that bind to the 2 AP-1 cis-acting elements found in
the ASBT promoter. Overexpression of c-jun transacti-
vates the system, whereas the system is quenched with a
dominant-negative c-jun. The dAP-1 element binds a
c-jun/c-fos heterodimer. Overexpression of c-fos represses
the activity of the ASBT promoter. The dAP-1 element
appears to be both necessary and sufficient to mediate
IL-1–mediated repression. Mutation of this element
abrogates its effect, whereas its incorporation into a
heterologous system imparts novel IL-1 responsivity.
The repressive effect of c-jun in this heterologous system
is presumed to be mediated after c-jun complexes with
preexisting c-fos that is endogenously expressed in the
cell lines. Alternatively, c-jun binding to the distal AP-1
element, in the absence of the positive-acting uAP-1
element may be sufficient to mediate transcriptional
repression.
The exact mechanism of the transcriptional repression
by c-fos is not clear. A cis-acting AP-1 element has been
shown to be involved in IL-1–mediated repression of
the 1-antichymotrypsin gene.45 Furthermore c-fos is a
negative transcriptional regulator of myogenin.46 Re-
Figure 10. A novel model for ASBT regulation. Under normal condi-
tions, c-jun binds to both uAP-1 and dAP-1 in the form of homodimer,
directing ASBT expression. As ileal inflammation occurs, such as in
Crohn’s disease, there is increased expression of the inflammatory
cytokine IL-1. It binds to the membrane surface receptor, initiating a
cascade of signal transduction involving phosphatidyl inositol 3 ki-
nase and, potentially, NF-B. Serine-phosphorylation of the target
protein c-fos facilitates its translocation from cytoplasm to nucleus
where it forms with c-jun a heterodimer, which subsequently binds to
dAP-1. This dAP-1/protein complex prevents the upstream c-jun dimer
from directing ASBT transcription.
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pression may only require physical interaction of c-fos
with the cognate DNA binding site, dAP-1. This may
explain why a dominant-negative c-fos, which lacks a
trans-activation domain, repressed ASBT transcription,
as well as a native c-fos expression construct. Binding of
the c-jun/c-fos complex distal to the transcriptional ini-
tiation site may physically interfere with transcript elon-
gation. IL-1 treatment is associated with the disappear-
ance of ABP-2, which involves uAP-1, and therefore
implies that binding by c-fos influences more than the
dAP-1 site. Further studies will be required to define the
exact mechanism by which c-fos binding inhibits ASBT
transcription. In cell lines and in rat ileal epithelium, the
transcriptional repression is associated with serine phos-
phorylation and nuclear translocation of c-fos. The bio-
logic relevance of and mechanisms for phosphorylation of
c-fos are not well understood.47
These studies have shown a new paradigm for the role
of AP-1 in the transcriptional regulation of the rat apical
sodium-dependent bile acid transporter (Figure 10). In-
testinal inflammation is associated with enhanced expres-
sion of proinflammatory cytokines. These proinflamma-
tory cytokines activate phosphatidylinositol 3-kinase and
NF-B to mediate downstream effects on c-jun, c-fos,
and other acute phase reacting proteins. The ASBT pro-
moter does not contain a recognizable NF-B binding
site. c-Fos is then phosphorylated and translocates into
the nucleus, where it binds to the distal cis-acting AP-1
element. Transcription is then repressed by either direct
physical effects on transcript elongation or indirect ef-
fects on the uAP-1–centered transcriptional complex.
Future studies will be needed to assess whether this
paradigm is also used in the repression of ASBT expres-
sion that has been observed during normal development
and in response to the adaptive response to surgical
resection of the intestine.48,49
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